- Home
- WYY vs CVKD Comparison
WYY vs CVKD Comparison
Compare WYY & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- CVKD
- Stock Information
- Founded
- WYY 1991
- CVKD 2022
- Country
- WYY United States
- CVKD United States
- Employees
- WYY N/A
- CVKD N/A
- Industry
- WYY EDP Services
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- WYY Technology
- CVKD Health Care
- Exchange
- WYY Nasdaq
- CVKD Nasdaq
- Market Cap
- WYY 35.6M
- CVKD 31.5M
- IPO Year
- WYY 1998
- CVKD 2023
- Fundamental
- Price
- WYY $2.87
- CVKD $16.75
- Analyst Decision
- WYY Strong Buy
- CVKD Strong Buy
- Analyst Count
- WYY 1
- CVKD 1
- Target Price
- WYY $7.00
- CVKD $32.00
- AVG Volume (30 Days)
- WYY 33.9K
- CVKD 22.9K
- Earning Date
- WYY 04-15-2025
- CVKD 05-08-2025
- Dividend Yield
- WYY N/A
- CVKD N/A
- EPS Growth
- WYY N/A
- CVKD N/A
- EPS
- WYY N/A
- CVKD N/A
- Revenue
- WYY $142,571,749.00
- CVKD N/A
- Revenue This Year
- WYY $7.92
- CVKD N/A
- Revenue Next Year
- WYY $10.18
- CVKD N/A
- P/E Ratio
- WYY N/A
- CVKD N/A
- Revenue Growth
- WYY 34.47
- CVKD N/A
- 52 Week Low
- WYY $1.83
- CVKD $5.70
- 52 Week High
- WYY $6.25
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- WYY 39.25
- CVKD 49.23
- Support Level
- WYY $2.50
- CVKD $14.10
- Resistance Level
- WYY $3.25
- CVKD $17.39
- Average True Range (ATR)
- WYY 0.45
- CVKD 1.57
- MACD
- WYY -0.01
- CVKD 0.04
- Stochastic Oscillator
- WYY 51.52
- CVKD 54.19
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically the company generates a majority of its revenue from the United States and rest from Europe.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.